Skip to main content

Biogen Inc.

BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000875045

In the last 90 days, Biogen Inc. insiders filed 0 open-market purchases and 1 sale; 1,046 institutions reported holding it in 13F filings for Q2 2026, worth $30.7B in total; no superinvestor holds it.

Superinvestors holding BIIB, Q2 2026

See all superinvestors

No superinvestor reported holding BIIB in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of BIIB each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q1 2024

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  2. Q4 2023

    1 superinvestor holding at quarter end

    New
    Maverick Capital
  3. Q3 2023

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  4. Q2 2023

    1 superinvestor holding at quarter end

    New
    Maverick Capital
  5. Q2 2022

    0 superinvestors holding at quarter end

    Sold out
    Southeastern Asset Management (Longleaf)
  6. Q1 2022

    1 superinvestor holding at quarter end

    Reduced
    Southeastern Asset Management (Longleaf) (−1.8%)
  7. Q4 2021

    1 superinvestor holding at quarter end

    New
    Southeastern Asset Management (Longleaf)
    Sold out
    Maverick Capital
  8. Q3 2021

    1 superinvestor holding at quarter end

    New
    Maverick Capital
  9. Q2 2021

    0 superinvestors holding at quarter end

    Sold out
    Berkshire Hathaway, Southeastern Asset Management (Longleaf)